Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.12
-3.2%
$12.33
$2.74
▼
$15.02
$3.80B1.593.28 million shs2.46 million shs
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$27.80
-8.2%
$29.52
$10.83
▼
$41.14
$3.84B-0.091.40 million shs1.58 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$76.59
-4.3%
$71.54
$40.00
▼
$99.50
$3.79B0.961.70 million shs817,334 shs
ODTX
Odyssey Therapeutics
$19.36
+1.1%
$20.45
$15.10
▼
$29.05
$966.16MN/A317,781 shs340,246 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%-3.28%-2.63%+2.59%+211.38%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+2.68%+15.00%+41.34%+138.69%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%+1.38%+40.75%-0.06%-11.06%
ODTX
Odyssey Therapeutics
0.00%-0.47%+11.47%-8.25%+1,913,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.12
-3.2%
$12.33
$2.74
▼
$15.02
$3.80B1.593.28 million shs2.46 million shs
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$27.80
-8.2%
$29.52
$10.83
▼
$41.14
$3.84B-0.091.40 million shs1.58 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$76.59
-4.3%
$71.54
$40.00
▼
$99.50
$3.79B0.961.70 million shs817,334 shs
ODTX
Odyssey Therapeutics
$19.36
+1.1%
$20.45
$15.10
▼
$29.05
$966.16MN/A317,781 shs340,246 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%-3.28%-2.63%+2.59%+211.38%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+2.68%+15.00%+41.34%+138.69%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%+1.38%+40.75%-0.06%-11.06%
ODTX
Odyssey Therapeutics
0.00%-0.47%+11.47%-8.25%+1,913,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.92
Moderate Buy$16.5548.79% Upside
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$43.7157.25% Upside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.79
Moderate Buy$124.1862.14% Upside
ODTX
Odyssey Therapeutics
2.80
Moderate Buy$34.6779.06% Upside

Current Analyst Ratings Breakdown

Latest ODTX, AMLX, ABCL, and IRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Reiterated RatingBuy
11/16/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Boost Price TargetOverweight$12.00 ➝ $20.00
11/11/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Boost Price TargetBuy$11.00 ➝ $15.00
11/10/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Boost Price TargetBuy$9.00 ➝ $14.00
11/10/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Boost Price TargetOutperform$38.00 ➝ $39.00
11/9/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Initiated CoverageBuy$132.00
11/6/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Boost Price TargetBuy$120.00 ➝ $127.00
11/6/2026
ODTX
Odyssey Therapeutics
Initiated CoverageBuy$40.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Set Price Target$45.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Initiated CoverageStrong-Buy
11/3/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M48.34N/AN/A$3.25 per share3.42
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M40.91N/AN/A$5.86 per share4.74
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$13.27 per shareN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/A$7.82 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.48N/AN/AN/A-218.54%-15.35%-10.84%N/A
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.44N/AN/AN/AN/A-41.54%-38.91%N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.34N/AN/AN/AN/A-36.33%-32.50%N/A
ODTX
Odyssey Therapeutics
N/A-$9.13N/AN/AN/AN/AN/AN/AN/A

Latest ODTX, AMLX, ABCL, and IRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1706-$0.13+$0.0406-$0.13$8.42 million$10.64 million
11/5/2026Q3 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3810-$0.38+$0.0010-$0.38$0.06 millionN/A
11/5/2026Q3 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.63-$1.53+$0.10-$1.53$1.88 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.43
12.77
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
26.81
26.81
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.10
20.30
24.14
ODTX
Odyssey Therapeutics
N/A
12.94
12.94

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
ODTX
Odyssey Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
ODTX
Odyssey Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562326.62 million233.86 millionOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136128.56 million114.55 millionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
16545.54 million43.83 millionOptionable
ODTX
Odyssey Therapeutics
10048.07 millionN/AN/A

Recent News About These Companies

What is HC Wainwright's Estimate for ODTX FY2026 Earnings?
What is HC Wainwright's Forecast for ODTX Q1 Earnings?
What is HC Wainwright's Estimate for ODTX Q1 Earnings?
Odyssey Therapeutics: Q3 earnings snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$11.12 -0.37 (-3.22%)
Closing price 04:00 PM Eastern
Extended Trading
$11.17 +0.05 (+0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$27.80 -2.49 (-8.22%)
Closing price 04:00 PM Eastern
Extended Trading
$27.78 -0.02 (-0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$76.59 -3.41 (-4.26%)
Closing price 04:00 PM Eastern
Extended Trading
$76.56 -0.03 (-0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Odyssey Therapeutics NASDAQ:ODTX

$19.36 +0.22 (+1.15%)
As of 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.